On Friday, Baird raised its price target on Instil Bio Inc (NASDAQ:TIL) shares significantly to $180 from the previous target of $32, while maintaining an Outperform rating. This substantial increase comes as the industry shows growing enthusiasm for the PD-1/L1xVEGF area of development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.